Latest filing published 05 Mar 2024 for Kinnate Biopharma Inc., €1,338.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Richard Thomas Williams: trading record in brief
All filings by Richard Thomas Williams on record concern Kinnate Biopharma Inc., in the capacity of senior executive. We count 9 filings; the first trade dates from 11 March 2022 and the latest from 1 March 2024.
The open-market record is one-sided, with 2 purchases worth €309k and not one sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 7 share grants.
Most recently, on 5 March 2024, the filings show a share grant worth €1,338 in Kinnate Biopharma Inc. The most recent open-market purchase was published on 15 March 2022, 1,699 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Richard Thomas Williams
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 558 shares@ US$2.591.0% of flowCommon StockSEC:0001415889-24-006754:0
- 541 shares@ US$2.250.9% of flowCommon StockSEC:0001209191-23-057457:0
- 541 shares@ US$2.350.9% of flowCommon StockSEC:0001209191-23-048424:0
- 541 shares@ US$4.301.7% of flowCommon StockSEC:0001209191-23-034445:0
- 638 shares@ US$5.212.4% of flowCommon StockSEC:0001209191-23-015875:0
- 541 shares@ US$7.753.1% of flowCommon StockSEC:0001209191-22-059515:0
- 25,000 shares0Common StockSEC:0001209191-22-048528:0
- 15,000 shares@ US$8.6490.1% of flowCommon StockSEC:0001209191-22-018866:0Canonical exit: 9 Jun 2022 (T+90)
8 of 8 declarations
